The safety warnings added by regulators to gout drug febuxostat should be reconsidered in light of new findings showing no increased risk of cardiovascular adverse events or mortality, rheumatologists say. Professor Nicola Dalbeth of Auckland University is one of several co-authors of a new paper that calls for reassessment of the cardiovascular safety of febuxostat ...
Call for FAST re-think on febuxostat cardiovascular warnings
By Michael Woodhead
28 Jan 2021